dc.contributor.author |
PARDESHI, KUNDANSINGH A. |
en_US |
dc.contributor.author |
KUMAR, T. ANAND |
en_US |
dc.contributor.author |
RAVIKUMAR, GOVINDAN |
en_US |
dc.contributor.author |
Shukla, Manjulika |
en_US |
dc.contributor.author |
Kaul, Grace |
en_US |
dc.contributor.author |
Chopra, Sidharth |
en_US |
dc.contributor.author |
CHAKRAPANI, HARINATH |
en_US |
dc.date.accessioned |
2019-04-25T07:00:12Z |
|
dc.date.available |
2019-04-25T07:00:12Z |
|
dc.date.issued |
2019-01 |
en_US |
dc.identifier.citation |
Bioconjugate Chemistry, 30(3), 751-759. |
en_US |
dc.identifier.issn |
1043-1802 |
en_US |
dc.identifier.uri |
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/2454 |
|
dc.identifier.uri |
https://doi.org/10.1021/acs.bioconjchem.8b00887 |
en_US |
dc.description.abstract |
Fluoroquinolones (FQs) are among the front-line antibiotics used to treat severe infections caused by Gram-negative bacteria. However, recently, due to toxicity concerns, their use has been severely restricted. Hence, efforts to direct delivery of this antibiotic specifically to bacteria/site of infection are underway. Here, we report a strategy that uses a bacterial enzyme for activation of a prodrug to generate the active antibiotic. The ciprofloxacin-latent fluorophore conjugate 1, which is designed as a substrate for nitroreductase (NTR), a bacterial enzyme, was synthesized. Upon activation by NTR, release of Ciprofloxacin (CIP) as well as a fluorescence reporter was observed. We provide evidence for the prodrug permeating bacteria to generate a fluorescent signal and we found no evidence for activation in mammalian cells supporting selectivity of activation within bacteria. As a testament to its efficacy, 1 was found to have potent bactericidal activity nearly identical to CIP and significantly reduced the bacterial burden in a neutropenic mouse thigh infection model, again, at comparable potency with CIP, a clinically used FQ. Thus, together, we have developed a small molecule that facilitates bacteria-specific fluoroquinolone delivery. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
American Chemical Society |
en_US |
dc.subject |
Cephalosporin 3-Quinolone Esters |
en_US |
dc.subject |
Dual-Action Cephalosporins |
en_US |
dc.subject |
Controlled-Release |
en_US |
dc.subject |
Escherichia-Coli |
en_US |
dc.subject |
Sulfur-Dioxide |
en_US |
dc.subject |
Prodrug |
en_US |
dc.subject |
Fluoroquinolones |
en_US |
dc.subject |
Derivatives |
en_US |
dc.subject |
Design |
en_US |
dc.subject |
Antibiotics |
en_US |
dc.subject |
TOC-APR-2019 |
en_US |
dc.subject |
2019 |
en_US |
dc.title |
Targeted Antibacterial Activity Guided by Bacteria-Specific Nitroreductase Catalytic Activation to Produce Ciprofloxacin |
en_US |
dc.type |
Article |
en_US |
dc.contributor.department |
Dept. of Chemistry |
en_US |
dc.identifier.sourcetitle |
Bioconjugate Chemistry |
en_US |
dc.publication.originofpublisher |
Foreign |
en_US |